$JBIO· SEC filing ·

JBIO to Host June 1 Conference Call on JADE101 Phase 1 Interim Data Showing Every-12-Week Subcutaneous Dosing Potential

Jade Biosciences, Inc. Common Stock · PHARMACEUTICAL PREPARATIONS · Now $18.59

-12% in 1h after detection

Post-detection moves

1h
-12%
1d
3d
7d
30d

Get alerts like this in real time

Push notifications the moment a signal fires. No spam, no crypto, no fluff.

Download for iOS